公开(公告)号：US20150343005A1

公开(公告)日：2015-12-03

申请号：US14759471

申请日：2014-01-10

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Jin Sook KIM ,  Jung Hyun KIM ,  Chan Sik KIM ,  Young Sook KIM ,  Eun Jin SHON ,  Yun Mi LEE ,  Dong Ho JUNG ,  Ik Soo LEE ,  Gyu Hyeong JO ,  Joo Hwan KIM

IPC: A61K36/25 ,  A61K31/155 ,  A61K36/708 ,  A61K36/488 ,  A23L1/30 ,  A61K36/482 ,  A61K36/45 ,  A61K36/73 ,  A61K36/87 ,  A61K36/718 ,  A61K36/16

CPC classification number: A61K36/25 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/155 ,  A61K36/16 ,  A61K36/45 ,  A61K36/482 ,  A61K36/488 ,  A61K36/708 ,  A61K36/718 ,  A61K36/73 ,  A61K36/87 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of Hedera helix leaves and Coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of Rheum palmatum, Puerariae radix, Ginkgo leaves, Cassiae semen, blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of Hedera helix leaves and Coptis chinensis.

Abstract translation: 本发明涉及一种用于预防，治疗或改善糖尿病并发症或血管性水肿的药物组合物和健康功能性食品组合物，其含有恒河螺旋叶和黄连的混合提取物作为活性成分。 更具体地，本发明涉及用于预防，治疗或改善糖尿病并发症或血管性水肿的药物组合物和健康功能性食品组合物，其进一步含有大黄，葛根，银杏叶，焦糖精，蓝莓，越桔，覆盆子的提取物 ，或葡萄籽作为活性成分，以及中草螺旋叶和黄连的混合提取物。

公开(公告)号：US20150335699A1

公开(公告)日：2015-11-26

申请号：US14440689

申请日：2013-11-06

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Hyun Kyoo SHIN ,  Ju Young JUNG ,  Hye Kyung HA ,  Chang Seob SEO ,  Young Jung KIM

IPC: A61K36/9064

CPC classification number: A61K36/9064 ,  A61K2236/33 ,  A61K2236/39

Abstract: The present invention relates to a composition including an Amomi Rotundus Fructus extract or a fraction thereof as an active ingredient, which can be used for the prevention, amelioration, or treatment of acute renal failure.

Abstract translation: 本发明涉及可用于预防，改善或治疗急性肾功能衰竭的组合物，该组合物包括作为活性成分的阿莫米us提取物或其一部分。

公开(公告)号：US20150283195A1

公开(公告)日：2015-10-08

申请号：US14441172

申请日：2013-11-06

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Hyun Kyoo Shin ,  Ju Young Jung ,  Hye Kyung Ha ,  Chang Seob Seo ,  Young Jung Kim

IPC: A61K36/53

CPC classification number: A61K36/53

Abstract: Disclosed is a composition including an Elsholtziae Herba extract as an active ingredient, which can be used for the prevention, improvement, or treatment of acute renal failure.

Abstract translation: 公开了一种组合物，其包含作为活性成分的榆树提取物，其可用于预防，改善或治疗急性肾衰竭。

公开(公告)号：US20250064879A1

公开(公告)日：2025-02-27

申请号：US18697698

申请日：2022-09-30

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE ,  DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Younghoon GO ,  Buyun KIM ,  Jae Kwang KIM ,  Jang-Gi CHOI ,  Tae Woo OH ,  Malk Eun PAK ,  Yeo Jin PARK ,  Jinsoo SEO ,  Hyein LEE

IPC: A61K36/258 ,  A61K36/484 ,  A61K36/539 ,  A61K36/718 ,  A61K36/725 ,  A61K36/8888 ,  A61K36/9068 ,  A61P25/28

Abstract: The present invention relates to a composition for treating, improving, or preventing Alzheimer's disease caused by ApoE4 gene mutation, the composition including Banha-Sasim-Tang as an active ingredient.
The composition including Banha-Sasim-Tang as an active ingredient of the present invention and a treatment method exhibit excellent effects of reducing amyloid beta proteins and inhibiting deposition thereof, which are specific to Alzheimer's disease caused by ApoE4 gene mutation, thereby having high applicability as a specific composition for preventing, improving, or treating Alzheimer's disease caused by ApoE4 gene mutation.

公开(公告)号：US12186356B2

公开(公告)日：2025-01-07

申请号：US17258253

申请日：2019-07-10

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Ho Kyoung Kim ,  Sun Haeng Park ,  Seol Jang

IPC: A61K36/744 ,  A23L5/20 ,  A23L33/00 ,  A23L33/105 ,  A61P17/04 ,  A61P37/08 ,  B01D11/02 ,  B01D15/12

Abstract: The present invention relates to a composition for preventing, alleviating, or treating allergic skin diseases comprising, as an active ingredient, an extract of gardenia fruit from which pigment is removed, and since the extract of gardenia fruit from which pigment is removed is more effective for allergic skin diseases compared to an extract of gardenia fruit from which pigment is not removed, the composition can be very advantageously used for allergic skin diseases, in particular, atopic dermatitis.

公开(公告)号：US20240252577A1

公开(公告)日：2024-08-01

申请号：US18290488

申请日：2022-05-31

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： HWAN SUCK CHUNG ,  JI HYE KIM ,  JANG GI CHOI ,  EUN-JI LEE ,  YOUNG SOO KIM

IPC: A61K36/73 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00

CPC classification number: A61K36/73 ,  A61K45/06 ,  A61P35/00 ,  A61P37/00 ,  A61K2236/331 ,  A61K2236/333

Abstract: A composition for inhibiting proliferation of tumor comprising Rubus coreanus extract as effective component. It was found that the Rubus coreanus extract binds to PD-L1 present on the surface of cancer cells, thus blocking the interaction between cancer cells and PD-1 on the surface of T cells to activate T cells and exhibit an inhibitory effect on tumor proliferation, and it was also found that the Rubus coreanus extract shows an excellent anti-tumor immune activity in humanized PD-1 animal model induced with MC38 colorectal cancer expressing human PD-L1 and also a synergistic effect when co-administered with anti-cancer agents.

公开(公告)号：US20240123015A1

公开(公告)日：2024-04-18

申请号：US18278227

申请日：2021-12-13

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Dong Seon KIM ,  Young Sook KIM ,  Heung Joo YUK ,  Yun Mi LEE ,  Yoon-Young SUNG ,  Eun Jung SON

IPC: A61K36/538 ,  A61P21/00

CPC classification number: A61K36/538 ,  A61P21/00 ,  A61K2236/331 ,  A61K2236/333

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

公开(公告)号：US11959131B2

公开(公告)日：2024-04-16

申请号：US16310236

申请日：2017-06-08

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Sangkyun Jeong ,  Soo A Oh

IPC: C12Q1/686 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6869 ,  C40B30/00 ,  G06F17/18 ,  G16B20/00 ,  G16B20/20 ,  G16B25/00 ,  G16B25/20

CPC classification number: C12Q1/686 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6869 ,  C40B30/00 ,  G06F17/18 ,  G16B20/00 ,  G16B20/20 ,  G16B25/00 ,  G16B25/20 ,  C12Q2549/119 ,  C12Q1/6806 ,  C12Q2549/119 ,  C12Q2531/113 ,  C12Q2535/122 ,  C12Q2563/179

Abstract: The present invention relates to a method for measuring a mutation rate, comprising preparing a library for next generation sequencing (NGS). Accordingly, the present invention can measure the effect of drugs, radiation, gene composition, aging, and various stresses experienced by an individual, etc. on the occurrence of mutations in a subject sample, and thus can be used for testing, diagnosis, management and evaluation related to toxicity tests, medical tests, maintenance and management of health, etc.

公开(公告)号：US11903957B2

公开(公告)日：2024-02-20

申请号：US17284592

申请日：2019-09-26

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Mi Young Lee ,  Yu Ri Kim ,  Young Hwa Kim ,  Bo-Kyung Park

IPC: A61K31/7048 ,  A23L33/105 ,  A23L33/125

CPC classification number: A61K31/7048 ,  A23L33/105 ,  A23L33/125

Abstract: A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

公开(公告)号：US11191801B2

公开(公告)日：2021-12-07

申请号：US15313341

申请日：2015-05-21

Applicant: KOREA INSTITUTE OF ORIENTAL MEDICINE

Inventor： Jin Sook Kim ,  Junghyun Kim ,  Chan-Sik Kim ,  Eunjin Shon ,  Yun Mi Lee ,  Sojin Choi ,  Ik Soo Lee ,  Young Sook Kim ,  Dong Ho Jung ,  Bo-Jeong Pyun ,  Seung-Hyun Jung

IPC: A61K36/54 ,  A61K36/65

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy, and angioedema, including macular (retinal) edema, macular degeneration, and varicose veins.